The Philadelphia Coalition for a Cure (PC4C) is planning to begin a diagnostic study of adult and pediatric brain tumours with NantHealth's GPS cancer test, in collaboration with Children's Hospital of Orange County (CHOC).
NantHealth, a personalised healthcare firm, will provide participating study researchers with its molecular profiling and diagnostic GPS cancer test, to identify treatment strategies for the patients.
The test is a molecular scan which integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry.
It enables determination of personalised treatment strategies by providing the molecular profile of a patient's cancer and an assessment of protein pathway function.
NantHealth founder and chief executive officer Patrick Soon-Shiong said: "The current standard of treatment for patients who have been diagnosed with brain tumours remains along the callous path of chemotherapy and/or radiation.
"Our goal in elevating the potential of combination immunotherapy as the new paradigm of cancer care is so that oncologists can offer their patients a less rigid therapy and one that is targeted at the patient's unique biology to harness the power of the immune system to fight cancer the way it was designed to do."
GPS cancer scanning is performed in CLIA-certified and CAP-accredited laboratories. It is currently available through Independence Blue Cross (Independence) for eligible members.
The PC4C intends to offer the test coverage for non-Independence insured brain tumour patients through grant support of the research study.
A clinical diagnostics and research initiative, PC4C aims to assess, promote and facilitate the use of technologies and clinical diagnostics on behalf of patients diagnosed with brain and other cancers.